Pancreatic adenocarcinoma pathway (WP4263)
Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors, Pancreatic Intraepithelial Neoplasia (PanINs: https://pathology.jhu.edu/pancreas/professionals/DuctLesions.php). The overexpression of HER-2/neu (ERBB2) and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene (CDKN2A) at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumor suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signaling pathway. The progression of disease and associated mutations is defined based on the arrow at the top, from left to right.
Authors
Kristina Hanspers and Egon WillighagenCited In
Organism
Homo sapiensCommunities
CPTAC Diseases PancCanNetAnnotations
Pathway Ontology: phosphatidylinositol 3-kinase-Akt signaling pathway cancer pathway disease pathway Jak-Stat signaling pathway
Disease Ontology: pancreatic adenocarcinoma
Cell Type Ontology: pancreatic ductal cell
Participants
References
- Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 2003 Jun;162(6):1807–15. PubMed Europe PMC Scholia
- Qi Z-H, Xu H-X, Zhang S-R, Xu J-Z, Li S, Gao H-L, et al. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Int J Oncol. 2018 Apr;52(4):1105–16. PubMed Europe PMC Scholia